Neurocrine Biosciences, Inc. (NBIX)
$
123.66
+0.63 (0.51%)
Key metrics
Financial statements
Free cash flow per share
4.9368
Market cap
11.9 Billion
Price to sales ratio
4.9298
Debt to equity
0.1765
Current ratio
3.1323
Income quality
1.7328
Average inventory
58.3 Million
ROE
0.1181
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company reported selling, general, and administrative expenses of $1,007,200,000.00 indicating its operational overhead costs. With an EBITDA of $639,700,000.00 a key indicator of the company's operational profitability, the EBITDA ratio is $0.27 highlighting the company's operational efficiency. Furthermore, the company incurred an income tax expense of $144,700,000.00 indicating its tax obligations. In addition, it reported depreciation and amortization expenses of $27,100,000.00 reflecting the wear and tear of its assets. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, along with clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia, complemented by commercial products like ONGENTYS for Parkinson's disease, ORILISSA for endometriosis pain management, and ORIAHNN for heavy menstrual bleeding associated with uterine fibroids. In clinical development, the company is exploring candidates such as NBI-921352 for pediatric and adult focal epilepsy, NBI-827104 for rare pediatric epilepsy and essential tremor, NBI-1065845 for major depressive disorder, NBI-1065846 for treating anhedonia in major depressive disorder, and NBI-118568 for schizophrenia. Neurocrine has established collaborations with various pharmaceutical entities, enhancing its development capabilities. In terms of market performance, the stock is reasonably priced at $123.66 appealing to a broad range of investors. It has an average trading volume of $1,529,632.00 indicating moderate liquidity. With a mid-range market capitalization of $12,238,110,828.00 the company is a steady performer within the sector. Neurocrine is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. As a part of the Healthcare sector, it continues to drive innovation and growth, positioning itself favorably for future developments.
Is Neurocrine Biosciences, Inc. (NBIX) a good investment?
Investing in Neurocrine Biosciences, Inc. (NBIX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Neurocrine Biosciences, Inc. (NBIX)'s stock forecast?
Analysts predict Neurocrine Biosciences, Inc. stock to fluctuate between $84.23 (low) and $157.98 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Neurocrine Biosciences, Inc.'s market capitalization?
As of 2025-05-29, Neurocrine Biosciences, Inc.'s market cap is $12,238,110,828, based on 98,965,800 outstanding shares.
How does Neurocrine Biosciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Neurocrine Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Neurocrine Biosciences, Inc. (NBIX) stock?
To buy Neurocrine Biosciences, Inc. (NBIX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for NBIX. Place an order (Market, Limit, etc.).
What is the best time to invest in Neurocrine Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Neurocrine Biosciences, Inc. perform in the last earnings report?
Revenue: $2,355,300,000 | EPS: $3.40 | Growth: 32.81%.
Where can I find Neurocrine Biosciences, Inc.'s investor relations reports?
Visit https://www.neurocrine.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Neurocrine Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Neurocrine Biosciences, Inc. stock?
All-time high: $157.98 (2024-08-01) | All-time low: $71.88 (2022-01-10).
What are the key trends affecting Neurocrine Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Tokyo, Japan and Cambridge, UK, 29 May 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona.
prnewswire.com
One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received CRENESSITY™ (crinecerfont) for up to one year. In addition, the study showed that for patients on CRENESSITY, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decreased glucocorticoid doses.
prnewswire.com
Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO™ study of INGREZZA, which was the first of its kind to specifically measure and report clinically meaningful improvements in the impact of tardive dyskinesia.
investors.com
Neurocrine Biosciences shares catapulted Tuesday on "surprising commercial momentum" for its newest drug, Crenessity.
schaeffersresearch.com
Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results.
seekingalpha.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q1 2025 Results Conference Call May 5, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Dr. Eiry Roberts - Chief Medical Officer Conference Call Participants Paul Matteis - Stifel Tazeen Ahmad - Bank of America Phil Nadeau - TD Cowen Brian Abrahams - RBC Capital Markets David Amsellem - Piper Sandler Anupam Rama - JPMorgan Josh Schimmer - Cantor Jay Olson - Oppenheimer Cory Kasimov - Evercore Brian Skorney - Baird Marc Goodman - Leerink Partners Mike Riad - Morgan Stanley Ash Verma - UBS Myles Minter - William Blair Laura Chico - Wedbush Operator Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode.
prnewswire.com
-- Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements1 SAN DIEGO , May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and reinforcing the need for routine screening, earlier diagnosis and treatment. The findings revealed that 80% of people living with tardive dyskinesia surveyed wished they had been screened for the condition earlier, and 86% wished their provider had discussed available treatment options for their uncontrolled movements sooner.1* The survey results come during Tardive Dyskinesia (TD) Awareness Week, May 4-10.
globenewswire.com
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568 (NBI-'568), an investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.
seekingalpha.com
Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product. Despite a recent sell-off due to missed earnings targets and cautious 2025 guidance, Neurocrine's pipeline, including the newly approved Crenessity, may offer substantial growth potential. The company's robust portfolio and promising pipeline, including potential blockbusters like Crenessity and Ingrezza (valbenazine) label expansions, make it an intriguing contrarian buy opportunity.
prnewswire.com
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.
See all news
